Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
CARE_CURR |
Age/sex: <1 Female |
2015 |
54 |
CARE_CURR |
Age/sex: <1 Male |
2015 |
12 |
CARE_CURR |
Age/sex: 1-4 Female |
2015 |
138 |
CARE_CURR |
Age/sex: 1-4 Male |
2015 |
30 |
CARE_CURR |
Age/sex: 10-14 Female |
2015 |
684 |
CARE_CURR |
Age/sex: 10-14 Male |
2015 |
138 |
CARE_CURR |
Age/sex: 15-19 Female |
2015 |
708 |
CARE_CURR |
Age/sex: 15-19 Male |
2015 |
138 |
CARE_CURR |
Age/sex: 20-24 Female |
2015 |
1,038 |
CARE_CURR |
Age/sex: 20-24 Male |
2015 |
216 |
CARE_CURR |
Age/sex: 25-49 Female |
2015 |
2,070 |
CARE_CURR |
Age/sex: 25-49 Male |
2015 |
402 |
CARE_CURR |
Age/sex: 5-9 Female |
2015 |
192 |
CARE_CURR |
Age/sex: 5-9 Male |
2015 |
42 |
CARE_CURR |
Age/sex: 50+ Female |
2015 |
108 |
CARE_CURR |
Age/sex: 50+ Male |
2015 |
30 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
1,068 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
222 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
3,924 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
786 |
CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2015 |
6,000 |
CARE_CURR |
Sum of Age/Sex disaggregates |
2015 |
6,000 |
CARE_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
6,000 |
CARE_SITE |
Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole |
2015 |
30 |
CARE_SITE |
Total number of PEPFAR supported sites providing clinical care services |
2015 |
35 |
GEND_GBV |
Age: 0-9 |
2015 |
50 |
GEND_GBV |
Age: 10-14 |
2015 |
200 |
GEND_GBV |
Age: 15-17 |
2015 |
100 |
GEND_GBV |
Age: 18-24 |
2015 |
100 |
GEND_GBV |
Age: 25+ |
2015 |
50 |
GEND_GBV |
By PEP service provision (related to sexual violence services provided) |
2015 |
100 |
GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2015 |
200 |
GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2015 |
300 |
GEND_GBV |
Number of people receiving post-GBV care |
2015 |
500 |
GEND_GBV |
Sex: Female |
2015 |
495 |
GEND_GBV |
Sex: Male |
2015 |
5 |
GEND_GBV |
Sum of Age disaggregates |
2015 |
500 |
GEND_GBV |
Sum of Sex disaggregates |
2015 |
500 |
HTS_TST |
Age/sex: <1 Female |
2015 |
270 |
HTS_TST |
Age/sex: <1 Female |
2015 |
270 |
HTS_TST |
Age/sex: <1 Male |
2015 |
60 |
HTS_TST |
Age/sex: <1 Male |
2015 |
60 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
690 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
690 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
150 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
150 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
2,820 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
2,820 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
1,290 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
1,290 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
2,640 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
2,640 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
1,590 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
1,590 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
3,390 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
3,390 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
2,880 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
2,880 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
7,350 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
7,350 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
5,010 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
5,010 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
960 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
960 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
210 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
210 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
540 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
540 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
150 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
150 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
4,740 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
1,710 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
13,920 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
9,630 |
HTS_TST |
Aggregated Age/sex: <15 Female |
2015 |
4,740 |
HTS_TST |
Aggregated Age/sex: <15 Male |
2015 |
1,710 |
HTS_TST |
Aggregated Age/sex: 15+ Female |
2015 |
13,920 |
HTS_TST |
Aggregated Age/sex: 15+ Male |
2015 |
9,630 |
HTS_TST |
By Test Result: Negative |
2015 |
25,800 |
HTS_TST |
By Test Result: Negative |
2015 |
25,800 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
30,000 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
30,000 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
30,000 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
30,000 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
6,450 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
6,450 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
23,550 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
23,550 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
30,000 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
30,000 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
30,000 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
30,000 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
4,200 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
4,200 |
LAB_CAP |
By clinical laboratories |
2015 |
12 |
LAB_CAP |
By site support type: Direct Service Delivery (DSD) |
2015 |
12 |
LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2015 |
12 |
LAB_CAP |
Sum of Site Support Type disaggregates |
2015 |
12 |
PMTCT_ARV |
Life-long ART (including Option B+) |
2015 |
400 |
PMTCT_ARV |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
30 |
PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
500 |
PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
400 |
PMTCT_ARV |
Single-dose nevirapine (with or without tail) |
2015 |
18 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
300 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
100 |
PMTCT_ARV |
Sum of New and Current disaggregates |
2015 |
400 |
PMTCT_ARV |
Sum of Regimen Type disaggregates |
2015 |
448 |
PMTCT_ARV_NGI |
Life-long ART (including Option B+) |
2015 |
400 |
PMTCT_ARV_NGI |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
30 |
PMTCT_ARV_NGI |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
500 |
PMTCT_ARV_NGI |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
400 |
PMTCT_ARV_NGI |
Single-dose nevirapine (with or without tail) |
2015 |
18 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
300 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
100 |
PMTCT_ARV_NGI |
Sum of New and Current disaggregates |
2015 |
400 |
PMTCT_ARV_NGI |
Sum of Regimen disaggregates |
2015 |
448 |
PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2015 |
150 |
PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2015 |
200 |
PMTCT_EID |
By infants with a positive virologic test result within 12 months of birth |
2015 |
15 |
PMTCT_EID |
Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) |
2015 |
1,250 |
PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2015 |
350 |
PMTCT_EID |
Sum of Infant Age disaggregates |
2015 |
350 |
PMTCT_STAT |
By: Known positives at entry |
2015 |
290 |
PMTCT_STAT |
By: Number of new positives identified |
2015 |
1,035 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2015 |
7,200 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
6,490 |
PMTCT_STAT |
Sum of Positives Status disaggregates |
2015 |
1,325 |
PMTCT_STAT_NGI |
By: Known positives at entry |
2015 |
290 |
PMTCT_STAT_NGI |
By: Number of new positives identified |
2015 |
1,035 |
PMTCT_STAT_NGI |
Number of new ANC and L&D clients |
2015 |
7,200 |
PMTCT_STAT_NGI |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
6,490 |
PMTCT_STAT_NGI |
Sum of Positives Status disaggregates |
2015 |
1,325 |
SITE_SUPP |
By program area/support type: Care and Support Direct Service Delivery (DSD) |
2015 |
35 |
SITE_SUPP |
By program area/support type: HTC Direct Service Delivery (DSD) |
2015 |
43 |
SITE_SUPP |
By program area/support type: Lab Direct Service Delivery (DSD) |
2015 |
12 |
SITE_SUPP |
By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) |
2015 |
10 |
SITE_SUPP |
By program area/support type: PMTCT Direct Service Delivery (DSD) |
2015 |
33 |
SITE_SUPP |
By program area/support type: TB/HIV Direct Service Delivery (DSD) |
2015 |
35 |
SITE_SUPP |
By program area/support type: Treatment Direct Service Delivery (DSD) |
2015 |
35 |
SITE_SUPP |
By program area/support type: VMMC Direct Service Delivery (DSD) |
2015 |
27 |
SITE_SUPP |
Number of unique sites supported by PEPFAR |
2015 |
43 |
TB_ART |
Age: 0-4 |
2015 |
6 |
TB_ART |
Age: 15+ |
2015 |
313 |
TB_ART |
Age: 5-14 |
2015 |
81 |
TB_ART |
Aggregated Age: <15 |
2015 |
87 |
TB_ART |
Aggregated Age: 15+ |
2015 |
313 |
TB_ART |
Female |
2015 |
280 |
TB_ART |
Known HIV-positive |
2015 |
50 |
TB_ART |
Male |
2015 |
120 |
TB_ART |
Newly tested |
2015 |
350 |
TB_ART |
Sum of Aggregated Age disaggregates |
2015 |
400 |
TB_ART |
Sum of Sex disaggregates |
2015 |
400 |
TB_ART |
Sum of Test Status disaggregates |
2015 |
400 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period |
2015 |
550 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2015 |
400 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
10 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
10 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
100 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
100 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
80 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
80 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
165 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
165 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
150 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
150 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
10 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
10 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
10 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
275 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
275 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
240 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
240 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
10,200 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
10,200 |
TX_CURR |
Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
5 |
TX_CURR |
Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
52 |
TX_CURR |
Sum of age/sex disaggregates |
2015 |
515 |
TX_CURR |
Sum of Age/Sex disaggregations |
2015 |
515 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
515 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
515 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
9,685 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
9,685 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
10,200 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
10,200 |
TX_CURR_NGI |
Age/Sex: <1 Female |
2015 |
10 |
TX_CURR_NGI |
Age/Sex: <1 Male |
2015 |
10 |
TX_CURR_NGI |
Age/Sex: 1-4 Female |
2015 |
100 |
TX_CURR_NGI |
Age/Sex: 1-4 Male |
2015 |
80 |
TX_CURR_NGI |
Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR_NGI |
Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR_NGI |
Age/Sex: 5-14 Female |
2015 |
165 |
TX_CURR_NGI |
Age/Sex: 5-14 Male |
2015 |
150 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Female |
2015 |
10 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Male |
2015 |
10 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Female |
2015 |
275 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Male |
2015 |
240 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Female |
2015 |
4,990 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Male |
2015 |
4,695 |
TX_CURR_NGI |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
10,200 |
TX_CURR_NGI |
Sum of Age/Sex disaggregates |
2015 |
10,200 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex <15 |
2015 |
515 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex 15+ |
2015 |
9,685 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex disaggregates |
2015 |
10,200 |
TX_NEW |
Aggregated Grouping by Age: <1 Male |
2015 |
10 |
TX_NEW |
Aggregated Grouping by Age/Sex: <1 Female |
2015 |
45 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2015 |
890 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2015 |
185 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2015 |
3,270 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2015 |
655 |
TX_NEW |
Breastfeeding status |
2015 |
350 |
TX_NEW |
By Age/Sex: <1 Female |
2015 |
45 |
TX_NEW |
By Age/Sex: <1 Male |
2015 |
10 |
TX_NEW |
By Age/Sex: 1-4 Female |
2015 |
115 |
TX_NEW |
By Age/Sex: 1-4 Male |
2015 |
25 |
TX_NEW |
By Age/Sex: 10-14 Female |
2015 |
570 |
TX_NEW |
By Age/Sex: 10-14 Male |
2015 |
115 |
TX_NEW |
By Age/Sex: 15-19 Female |
2015 |
590 |
TX_NEW |
By Age/Sex: 15-19 Male |
2015 |
115 |
TX_NEW |
By Age/Sex: 20-24 Female |
2015 |
865 |
TX_NEW |
By Age/Sex: 20-24 Male |
2015 |
180 |
TX_NEW |
By Age/Sex: 25-49 Female |
2015 |
1,725 |
TX_NEW |
By Age/Sex: 25-49 Male |
2015 |
335 |
TX_NEW |
By Age/Sex: 5-9 Female |
2015 |
160 |
TX_NEW |
By Age/Sex: 5-9 Male |
2015 |
35 |
TX_NEW |
By Age/Sex: 50+ Female |
2015 |
90 |
TX_NEW |
By Age/Sex: 50+ Male |
2015 |
25 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2015 |
5,000 |
TX_NEW |
Pregnancy status |
2015 |
1,100 |
TX_NEW |
Sum of Age/Sex disaggregates |
2015 |
5,000 |
TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2015 |
5,000 |
TX_RET |
Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
300 |
TX_RET |
Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
1,900 |
TX_RET |
Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
800 |
TX_RET |
Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
1,100 |
TX_RET |
Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
1,900 |
TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2015 |
2,800 |
TX_RET |
Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
600 |
TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2015 |
3,000 |
TX_RET_den |
Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
300 |
TX_RET_den |
Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
1,800 |
TX_RET_den |
Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
700 |
TX_RET_den |
Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
1,000 |
TX_RET_den |
Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
1,800 |
TX_RET_den |
Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
700 |
VMMC_AE |
By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s) |
2015 |
25 |
VMMC_AE |
Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) |
2015 |
25 |
VMMC_AE |
Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s) |
2015 |
25 |
VMMC_CIRC |
By Age: 10-14 |
2015 |
868 |
VMMC_CIRC |
By Age: 10-14 |
2015 |
96 |
VMMC_CIRC |
By Age: 15-19 |
2015 |
420 |
VMMC_CIRC |
By Age: 15-19 |
2015 |
44 |
VMMC_CIRC |
By Age: 20-24 |
2015 |
465 |
VMMC_CIRC |
By Age: 20-24 |
2015 |
49 |
VMMC_CIRC |
By Age: 25-49 |
2015 |
370 |
VMMC_CIRC |
By Age: 25-49 |
2015 |
44 |
VMMC_CIRC |
By Age: 50+ |
2015 |
127 |
VMMC_CIRC |
By Age: 50+ |
2015 |
17 |
VMMC_CIRC |
By circumcision technique: Surgical VMMC |
2015 |
2,250 |
VMMC_CIRC |
By circumcision technique: Surgical VMMC |
2015 |
250 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery |
2015 |
400 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery |
2015 |
100 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2015 |
1,830 |
VMMC_CIRC |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2015 |
150 |
VMMC_CIRC |
By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site |
2015 |
120 |
VMMC_CIRC |
By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site |
2015 |
33 |
VMMC_CIRC |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2015 |
1,973 |
VMMC_CIRC |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2015 |
174 |
VMMC_CIRC |
By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) |
2015 |
157 |
VMMC_CIRC |
By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) |
2015 |
43 |
VMMC_CIRC |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2015 |
2,250 |
VMMC_CIRC |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2015 |
250 |
VMMC_CIRC |
Sum of age disaggregates |
2015 |
250 |
VMMC_CIRC |
Sum of Age disaggregations |
2015 |
2,250 |
VMMC_CIRC_NGI |
By Age: 10-14 |
2015 |
964 |
VMMC_CIRC_NGI |
By Age: 15-19 |
2015 |
464 |
VMMC_CIRC_NGI |
By Age: 20-24 |
2015 |
514 |
VMMC_CIRC_NGI |
By Age: 25-49 |
2015 |
414 |
VMMC_CIRC_NGI |
By Age: 50+ |
2015 |
144 |
VMMC_CIRC_NGI |
By circumcision technique: Surgical VMMC |
2015 |
2,500 |
VMMC_CIRC_NGI |
By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery |
2015 |
534 |
VMMC_CIRC_NGI |
By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery |
2015 |
1,916 |
VMMC_CIRC_NGI |
By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site |
2015 |
142 |
VMMC_CIRC_NGI |
By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) |
2015 |
2,109 |
VMMC_CIRC_NGI |
By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) |
2015 |
199 |
VMMC_CIRC_NGI |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2015 |
2,500 |
VMMC_CIRC_NGI |
Sum of Age disaggregates |
2015 |
2,500 |